An Evaluation of Risperidone Dosing for Pediatric Delirium in Children Less Than or Equal to 2 Years of Age
| Autor: | Erin Grey, Kalen B. Manasco, Jennifer Munoz-Pareja, Christopher T. Campbell |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Adolescent Critical Care medicine.medical_treatment Sedation Intensive Care Units Pediatric Drug Administration Schedule Cohort Studies 03 medical and health sciences 0302 clinical medicine 030225 pediatrics medicine Humans Pharmacology (medical) 030212 general & internal medicine Dosing Child Antipsychotic Adverse effect Retrospective Studies Risperidone Dose-Response Relationship Drug business.industry Age Factors Delirium Discontinuation Tolerability Child Preschool Female medicine.symptom business Antipsychotic Agents medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 54:464-469 |
| ISSN: | 1542-6270 1060-0280 |
| DOI: | 10.1177/1060028019891969 |
| Popis: | Background: Risperidone dosing and safety data are limited in patients ≤2 years of age. Objective: To describe the dosing strategies, safety, and tolerability of risperidone in infants ≤2 years of age. Methods: An institutional review board–approved retrospective study was conducted in a 24-bed pediatric intensive care unit at an academic medical center in patients ≤2 years of age receiving risperidone for the management of ICU delirium. The primary outcome was mean initial daily dose of risperidone. Secondary outcomes included mean daily dose, dosing frequency, treatment duration, and adverse effects. Results: Seventeen patients who received at least 1 dose of risperidone were included in the study. The initial daily dose ranged from 0.1 to 0.25 mg (0.01-0.04 mg/kg), with a mean of 0.17 mg (0.02 mg/kg). Most patients were initiated on once-daily dosing (76.5%) versus twice-daily dosing (17.6%). More than 80% of patients required a dose increase during therapy. Median daily doses of fentanyl, morphine, ketamine, and midazolam were decreased following initiation of risperidone. No adverse events that led to discontinuation of risperidone were reported. Conclusion and Relevance: Risperidone was found to be safe and well tolerated at daily doses of risperidone of 0.1 to 0.25 mg in 1 or 2 doses per day in patients ≤2 years old for the management of ICU delirium. To our knowledge, these results provide the largest cohort describing dosing recommendations specific for risperidone in this age group. Further investigation on the effect of antipsychotic administration on other sedation and analgesic regimens is necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|